7251-53-8

Basic information

• Product Name: ethyl 3-hydroxy-1H-pyrazole-4-carboxylate
• Synonyms: ethyl 3-hydroxy-1H-pyrazole-4-carboxylate;1H-Pyrazole-4-carboxylicacid, 2,3-dihydro-3-oxo-, ethyl ester;4-(Ethoxycarbonyl)-3-hydroxy-1H-pyrazole;ethyl 3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate;3-Oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid ethyl ester;Ethyl 5-hydroxy-1H-pyrazole-4-carboxylate;ethyl 3-oxo-1,2-dihydropyrazole-4-carboxylate;3-Hydroxy-1H-Pyrazole-4-Carboxylic Acid Ethyl Ester(WX649081)
• CAS NO: 7251-53-8
• Molecular Formula: C₆H₈N₂O₃
• Molecular Weight: 156.13932
• Mol File: 7251-53-8.mol

Chemical Properties

• Melting Point: 140-142 °C
• Boiling Point: 311.7°C at 760 mmHg
• Flash Point: 142.3°C
• Appearance: /
• Density: 1.272g/cm³
• Vapor Pressure: 0.000302mmHg at 25°C
• Refractive Index: 1.496
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.78±0.70(Predicted)
• CAS DataBase Reference: ethyl 3-hydroxy-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-hydroxy-1H-pyrazole-4-carboxylate(7251-53-8)
• EPA Substance Registry System: ethyl 3-hydroxy-1H-pyrazole-4-carboxylate(7251-53-8)

Safety Data

• Hazardous Substances Data: 7251-53-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
Ethyl 3-hydroxy-1H-pyrazole-4-carboxylate is used as a key intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows for the creation of various chemical entities that can be further explored for their therapeutic properties.
Used in Chemical Research:
In the field of chemical research, ethyl 3-hydroxy-1H-pyrazole-4-carboxylate is used as a reagent in various chemical reactions. Its versatility in forming different chemical compounds makes it an essential component in the synthesis of a wide range of chemical products.
Used in Scientific Experiments:
Ethyl 3-hydroxy-1H-pyrazole-4-carboxylate is employed as a reactant in scientific experiments, where its reactivity and properties are studied to understand its behavior under different conditions. This knowledge can be applied to develop new methodologies and techniques in chemical synthesis.

InChI:InChI=1/C6H8N2O3/c1-2-11-6(10)4-3-7-8-5(4)9/h3H,2H2,1H3,(H2,7,8,9)

Upstream product

• 6296-99-7 diethyl aminomethylenemalonate 
• 141-52-6 sodium ethanolate 
• 39513-55-8 1,3-dimethyluracil-5-carbohydrazide 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 
• 18856-68-3 diethyl N,N-dimethylaminomethylenemalonate 
• 49597-05-9 propene-1,1,3,3-tetracarboxylic acid tetraethyl ester 

Downstream Products

• 1173003-60-5 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid ethyl ester 
• 103626-04-6 ethyl 3-methoxy-1-methyl-1H-pyrazole-4-carboxylate 
• 178424-17-4 1-(tert-butyl) 4-ethyl 3-hydroxy-1H-pyrazole-1,4-dicarboxylate 
• 342024-08-2 ethyl 1-benzyl-3-benzyloxy-1H-pyrazole-4-carboxylate 
• 342023-74-9 ethyl 1-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]benzyl]-3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]benzyloxy]-1H-pyrazole-4-carboxylate 
• 342024-75-3 ethyl 1-(4-phenoxybenzyl)-3-(4-phenoxybenzyloxy)-1H-pyrazole-4-carboxylate 
• 76205-19-1 1-(para-chlorophenyl)-3-hydroxypyrazole 
• 478968-48-8 ethyl 3-methoxy-1H-pyrazole-4-carboxylate 
• 178424-16-3 3-[[(4-methoxyphenyl)methyl]oxy]pyrazole-4-carboxylic acid ethyl ester 
• 332070-62-9 ethyl 3-ethoxy-1-ethylpyrazole-4-carboxylate 

Relevant articles and documents

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.

Preparation method of pyraclostrobin intermediate

The invention discloses a preparation method of pyraclostrobin intermediate 3 - hydroxyl - 1H - pyrazole and 1 - (4 - chlorophenyl) -3 - pyrazol, which comprises: synthesizing 3 - hydroxyl - 1H - pyrazole -4 - carboxylic acid ethyl ester by cyclization re

PROCESS OF MAKING CFTR MODULATORS

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The disclosure provides processes for preparing a compound of Formula (I).

SOLID FORMS OF MODULATORS OF CFTR

Crystalline and amorphous forms of a potassium salt of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID RECEPTOR AGONIST-RELATED DISEASES

The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (for example, headache) can be treated or prevented.

CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS

Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

MORPHINAN DERIVATIVE

A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(=O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Preparation method of topramezone

The invention discloses a preparation method of topramezone. The particularly comprises the steps of carrying out cyclization, methylation, hydrolysis, amidation, Grignard reaction, oxidation and demethylation on 2-(alkoxymethylene)malonate as a raw material, so as to obtain a target product, wherein the yield of the target product reaches 61.8%-63.2%. According to the preparation method, the raw materials such as a palladium/platinum catalyst which is high in cost and difficult to recycle, a virulent rearrangement catalyst and high-cost methylhydrazine are not adopted, and the preparation method which is low in cost, easy in operation, low in pollution and accordant with large-scale industrial production requirements is provided.